The US Food and Drug Administration-led Project Orbis and other international regulatory collaborations often provide reassuring validation when a health authority is struggling with a challenging drug application, regulators said at the recent American Society of Clinical Oncology annual meeting.
Given the confidentiality restrictions regulatory authorities must follow, it is reassuring to “exit our comfort zone and confront other regulators”...








